This report examines how biosimilars can improve affordability and access while maintaining high-quality care, yet remain underutilized in many markets. It analyzes barriers such as provider hesitancy, complex reimbursement structures, formulary design, and limited patient awareness. Using case studies and market data, the report shows how targeted education, aligned incentives, and supportive policy frameworks can accelerate biosimilar adoption. It emphasizes the need for predictable market conditions that balance price competition with sustainability, ensuring long-term savings without discouraging future entrants. Unlocking biosimilar potential is positioned as a critical lever for healthcare system resilience.

Join for free to read